Article type
Abstract
Background: Frailty is associated with a variety of diseases, including metabolic syndrome, and can result in multiple adverse health outcomes. It is critical to identify the prevalence of frailty among patients with metabolic syndrome, however, the prevalence reported in the literature varies widely.
Objectives: To pool the overall prevalence of frailty among patients with metabolic syndrome.
Methods: The Cochrane Library, PubMed, Web of Science, Embase, APA, Scopus, CINAHL Complete, CNKI, Wan Fang, SinoMed, and VIP databases were searched from the inception to June 19, 2022. Statistical analysis was performed using STATA 15 software. The prevalence was pooled using the random-effects model. The sources of heterogeneity were investigated by using meta-regression and subgroup analyses.
Results: A total of 18 original studies published between 2007 and 2022 were included in this systematic review and meta-analysis, involving 9201 metabolic syndrome patients. The prevalence of frailty and pre-frailty among patients with metabolic syndrome was 19% (95% CI:10% to 30%, I²=99.28%) and 48% (95% CI:31% to 64%, I²=98.83%). Subgroup analyses revealed differences in prevalence by frailty scales, geographic regions, study settings, publication years, study quality, study design, and different components of metabolic syndrome.
Conclusions: This systematic review and meta-analysis showed the high prevalence of frailty and pre-frailty in patients with metabolic syndrome. The high prevalence of frailty in patients with metabolic syndrome should be taken seriously, and physicians and nurses should enhance and take appropriate assessments and measures to improve their health. In the future, more high-quality longitudinal studies and exploration of other potential demographic characteristics that may influence frailty are needed to understand more information on frailty in patients with metabolic syndrome.
Objectives: To pool the overall prevalence of frailty among patients with metabolic syndrome.
Methods: The Cochrane Library, PubMed, Web of Science, Embase, APA, Scopus, CINAHL Complete, CNKI, Wan Fang, SinoMed, and VIP databases were searched from the inception to June 19, 2022. Statistical analysis was performed using STATA 15 software. The prevalence was pooled using the random-effects model. The sources of heterogeneity were investigated by using meta-regression and subgroup analyses.
Results: A total of 18 original studies published between 2007 and 2022 were included in this systematic review and meta-analysis, involving 9201 metabolic syndrome patients. The prevalence of frailty and pre-frailty among patients with metabolic syndrome was 19% (95% CI:10% to 30%, I²=99.28%) and 48% (95% CI:31% to 64%, I²=98.83%). Subgroup analyses revealed differences in prevalence by frailty scales, geographic regions, study settings, publication years, study quality, study design, and different components of metabolic syndrome.
Conclusions: This systematic review and meta-analysis showed the high prevalence of frailty and pre-frailty in patients with metabolic syndrome. The high prevalence of frailty in patients with metabolic syndrome should be taken seriously, and physicians and nurses should enhance and take appropriate assessments and measures to improve their health. In the future, more high-quality longitudinal studies and exploration of other potential demographic characteristics that may influence frailty are needed to understand more information on frailty in patients with metabolic syndrome.